Intellia Therapeutics/ US45826J1051 /
2024-04-25 9:59:59 PM | Chg. -1.13 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
20.03USD | -5.34% | 41,241 Turnover: 823,752.60 |
-Bid Size: - | -Ask Size: - | 20.63 | 19.65 |
GlobeNewswire
03-18
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a...
GlobeNewswire
02-22
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights R...
GlobeNewswire
02-15
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene...
GlobeNewswire
02-14
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings ...
GlobeNewswire
01-31
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patien...
GlobeNewswire
01-24
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmento...
GlobeNewswire
01-04
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milest...
GlobeNewswire
2023-12-12
Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integrat...
GlobeNewswire
2023-11-14
Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigatio...
GlobeNewswire
2023-11-09
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company P...
GlobeNewswire
2023-11-03
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blo...
GlobeNewswire
2023-11-02
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th Internatio...
GlobeNewswire
2023-10-26
Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatm...
GlobeNewswire
2023-10-18
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initi...
GlobeNewswire
2023-10-13
Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Ag...
GlobeNewswire
2023-10-03
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies fo...
GlobeNewswire
2023-10-03
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies fo...
GlobeNewswire
2023-08-30
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phas...
GlobeNewswire
2022-03-09
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of A...
GlobeNewswire
2022-03-01
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for th...